FDA approves Lilly's Jaypirca as first-line CLL therapy

· Health · United States

Eli Lilly's Jaypirca won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma, making it the first therapy cleared for first-line use in CLL. BioPharma Dive noted the FDA endorsed broader use of a Lilly medicine in the same roundup that covered Roche's Alector deal and CSL's licensing agreement. In related pipeline news, Genmab reported a 45.9% objective response rate for its FRα-directed ADC Rina-S in platinum-resistant ovarian cancer.

Why it matters：First-line clearance for a BTK inhibitor expands the competitive field in CLL and shifts treatment sequencing for hematologists.

Key points

  • Jaypirca is approved for previously untreated CLL and SLL.
  • It is the first therapy cleared for first-line CLL use.
  • Genmab reported 45.9% response for Rina-S in ovarian cancer.

Sources (original reporting)

More stories from this day